NHSN COVID-19 Hospital Module

[NCEZID] National Healthcare Safety Network (NHSN) Coronavirus (COVID-19) Surveillance in Healthcare Facilities

Hospital COVID Data Form - webform_FINAL

OMB: 0920-1317

Document [docx]
Download: docx | pdf

O MB no.???-????

Exp. Date: ??/??/????

www.cdc.gov/nhsn

Page 7 of 7

COVID-19 Hospital Data Form

*Required for submission

Entering Data For


Facility Information

1

a.

Facility Name*



h.

HHS ID*



b.

CCN*




AHA ID



c.

NHSN Org ID*




Facility Type*



d.

State*



e.

County*



f.

ZIP*



g.

TeleTracking ID*


Hospitals, with the exception of psychiatric and rehabilitation hospitals, are required to report seven days a week but, where possible and pending further direction from their state or jurisdiction, are encouraged to report weekend data on the following Monday with the data backdated to the appropriate date. See HHS Guidance & FAQ.

It is critical to the COVID-19 response that all of the information listed below is provided to the Federal Government on the requested reporting schedule to facilitate planning, monitoring, and resource allocation during the COVID-19 Public Health Emergency (PHE). All fields are mandatory unless otherwise noted in the HHS Guidance & FAQ.


Note: Provide data entries for all requested fields. Enter 0 or select N/A (if available) if the item is not applicable at your facility.


Staffed Bed Capacity

3a. All hospital inpatient beds*


4a. All hospital inpatient bed occupancy*


5a. ICU beds*


6a. ICU bed occupancy*










3b. Adult hospital inpatient beds*


4b. Adult hospital inpatient bed occupancy*


5b. Adult ICU beds*


6b. Adult ICU bed occupancy*










3c. All inpatient pediatric beds *


4c. Pediatric inpatient bed occupancy*


5c. Pediatric ICU beds*


6c. Pediatric ICU bed occupancy*











Hospitalizations

9a. Total hospitalized adult suspected or laboratory-confirmed COVID-19 patients*


10a. Total hospitalized pediatric suspected or laboratory confirmed COVID-19 patients*


11. Hospitalized and ventilated COVID-19 patients*


12a Total ICU adult suspected or laboratory-confirmed COVID-19 patients*








9b. Hospitalized adult laboratory confirmed COVID-19 patients*


10b. Hospitalized pediatric laboratory-confirmed COVID-19 patients*




12b. Hospitalized ICU adult laboratory-confirmed COVID-19 patients*














12c. Hospitalized ICU pediatric laboratory-confirmed COVID-19 patients*








13. Hospital onset















Emergency Department


19. Previous day’s ED Visits*


20. Previous day’s total COVID-19- related ED visits*













Previous Day’s Admissions

Note: The age brackets under fields 17a and 17b are required to be considered compliant.

Previous Day’s adult admissions with laboratory-confirmed COVID-19 and breakdown by age bracket:


Previous Day’s adult admissions with suspected COVID-19 and breakdown by age bracket:


Previous Day’s pediatric admissions with laboratory confirmed COVID-19 breakdown by age bracket:


Previous Day’s pediatric admissions with suspected COVID-19:


17a. Total adult*


17b. Total adult*


18a. Total pediatric*


18b. Total pediatric*


















18-19


18-19


0-4












20-29


20-29


5-11












30-39


30-39


12-17












40-49


40-49


Unknown












50-59


50-59














60-69


60-69














70-79


70-79














80+


80+














Unknown


Unknown















Therapeutics

Note: For fields 39a - 40d below, report one time a week on Wednesday.

Casirivimab (REGN10933) / Imdevimab

(REGN10987) (Therapeutic A)


Bamlanivimab and Etesevimab

(Therapeutic C)


Sotrovimab (Therapeutic D)






39a. Current inventory on hand (in course)*


40a. Current inventory on hand (in course)*


40c. Current inventory on hand (in course)*






39b. Courses used in the last week*


40b. Courses used in the last week*


40d. Courses used in the last week*







Staff

Note: Field 24 will always default to “No” for a new submission.

24. Critical staffing shortage anticipated within a week (Y/N)*








PPE


27b. N95 respirators*


30c. N95 respirators*










27c. Surgical and procedure masks*


30e. Surgical and procedure masks*










27d. Eye protection including face shields and goggles*


30f. Eye protection including face shields and goggles*








27e. Single-use gowns*


30g. Single-use gowns*








27f. Exam gloves (sterile and non-sterile)*


30h. Exam gloves*
























Influenza

33. Total hospitalized patients with laboratory-confirmed influenza virus infection*


34. Previous day's influenza admissions (laboratory-confirmed influenza virus infection)*


35. Total hospitalized ICU patients with laboratory-confirmed influenza virus infection*









Inactive Federal Data Collection


The below fields have been made inactive for the federal data collection. Hospitals no longer need to report these data elements to the federal government.


Note: State, local, tribal, and territorial (SLTT) partners may have reporting requirements related to or independent of the federal reporting requirements. Facilities are encouraged to work with relevant (SLTT) partners to ensure complete reporting for all partners.



Staffed Bed Capacity


2a. All hospital beds










2b. All adult hospital beds











Ventilators


7. Total mechanical ventilators


8. Mechanical ventilators in use









ED/Overflow


14. ED/overflow


15. ED/overflow and ventilated









Previous Day's COVID-19 Deaths

16. Previous Day's COVID-19 Deaths











Therapeutics



Remdesivir




Bamlanivimab (Therapeutic B)




21. Previous day's Remdesivir used (Optional)


39c. Current inventory on hand (in courses) (Optional)








22. Current inventory (Optional)


39d. Courses used in the last week (Optional)










Please note: Bamlanivimab is no longer authorized for use without accompanying Etesevimab. The value in the field 39d should be 0. Any doses of Bamlanivimab used with accompanying Etesevimab should be reported in field 40b.










Staff


23. Critical staffing shortage today (Y/N) (Optional)


25. Staffing shortage details (Optional)

















PPE


26. PPE Supplies



27. On hand supply (DURATION IN DAYS):



28. On hand supply (INDIVIDUAL

UNITS/”EACHES”) (Optional):




29. Are you able to obtain these items?

Are your PPE supply items managed (purchased, allocated,

and/or stored) at the facility level or, if you are part of a health

system, at the health system level (or other multiple facility

group)?








27a. Ventilator supplies


28a. N95 respirators (Optional)


29a. Ventilator supplies (any supplies excluding medications)












28b. Other respirators such as PAPRs or elastomerics (Optional)


29b. Ventilator medications












28c. Surgical and procedure masks (Optional)


29c. N95 Respirators












28d. Eye protection including face shields and goggles (Optional)


29d. Other respirators such as PAPRs or elastomerics












28e. Single-use gowns (Optional)


29e. Surgical and procedure masks












28f. Launderable gowns (Optional)


29f. Eye protection including face shields and goggles



















28g. Exam gloves (single) (Optional)


29g. Single-use gowns














29h. Exam gloves














29i. Are you able to maintain a supply of launderable gowns?

















30. Are you able maintain at least a three-day supply of these items?



31. Does your facility re-use or extend the use of PPE? (Optional)









32. If there are any critical issues, such as supply, staffing,

capacity, or other issues about which you would like to

receive direct contact, please explain here. (Optional)



30a. Ventilator supplies (any supplies excluding medications)


31a. Reusable/launderable isolation gowns











30b Ventilator medications


31b. PAPRs or elastomerics












30d. Other respirators such as PAPRS or elastomerics


31c. N95 respirators












30i. Laboratory - nasal pharyngeal swabs














30j. Laboratory - nasal swabs














30k. Laboratory - viral transport media















Influenza







36. Total hospitalized patients co-infected with BOTH laboratory-confirmed COVID-19 AND laboratory-confirmed influenza virus infection (Optional)


37. Previous day's influenza deaths (laboratory-confirmed influenza virus infection) (Optional)


38. Previous day's deaths for patients co-infected with both COVID-19 AND laboratory-confirmed influenza virus (Optional)










Vaccinations

Vaccinations for Personnel




41. Previous week’s COVID-19 vaccination doses administered to healthcare personnel by your facility (Regardless of series

or single-dose vaccine) (Optional)


42. Current healthcare personnel who have not yet received any COVID-19 vaccination doses (Optional)


43. Current healthcare personnel who have received the first dose of COVID-19 vaccination doses (Optional)


44. Current healthcare personnel who have received a completed series of a COVID-19 vaccination or a single-dose vaccination












45. Total number of current healthcare personnel (Optional)




















Vaccinations for Patients




46. Previous week's number of patients and other nonhealthcare personnel who received the first dose in a multi-series of COVID-19 vaccination doses (Optional)


47. Previous week's number of patients who received the final dose in a series of COVID-19 vaccination doses or the single-dose vaccine by your facility (Optional)

















File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorSmith, Henrietta (CDC/DDID/NCEZID/DHQP)
File Modified0000-00-00
File Created2023-08-28

© 2024 OMB.report | Privacy Policy